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ARTICLE
BAFopathies’ DNA methylation epi-signatures
demonstrate diagnostic utility and functional
continuum of Cofﬁn–Siris and Nicolaides–Baraitser
syndromes
Erfan Aref-Eshghi1,2, Eric G. Bend3, Rebecca L. Hood4, Laila C. Schenkel1,2, Deanna Alexis Carere2,
Rana Chakrabarti5, Sandesh C.S. Nagamani6, Sau Wai Cheung 6, Philippe M. Campeau 7, Chitra Prasad5,
Victoria Mok Siu5, Lauren Brady8, Mark A. Tarnopolsky8, David J. Callen8, A. Micheil Innes 9,
Susan M. White10, Wendy S. Meschino11, Andrew Y. Shuen5, Guillaume Paré12, Dennis E. Bulman4,
Peter J. Ainsworth1,2, Hanxin Lin1,2, David I. Rodenhiser5,13, Raoul C. Hennekam14, Kym M. Boycott4,
Charles E. Schwartz15 & Bekim Sadikovic1,2
Cofﬁn–Siris and Nicolaides–Baraitser syndromes (CSS and NCBRS) are Mendelian disorders
caused by mutations in subunits of the BAF chromatin remodeling complex. We report
overlapping peripheral blood DNA methylation epi-signatures in individuals with various
subtypes of CSS (ARID1B, SMARCB1, and SMARCA4) and NCBRS (SMARCA2). We demon-
strate that the degree of similarity in the epi-signatures of some CSS subtypes and NCBRS
can be greater than that within CSS, indicating a link in the functional basis of the two
syndromes. We show that chromosome 6q25 microdeletion syndrome, harboring ARID1B
deletions, exhibits a similar CSS/NCBRS methylation proﬁle. Speciﬁcity of this epi-signature
was conﬁrmed across a wide range of neurodevelopmental conditions including other
chromatin remodeling and epigenetic machinery disorders. We demonstrate that a machine-
learning model trained on this DNA methylation proﬁle can resolve ambiguous clinical cases,
reclassify those with variants of unknown signiﬁcance, and identify previously undiagnosed
subjects through targeted population screening.
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BRG1/BRM-associated factor (BAF) is a chromatin remo-deling complex which plays an integral role in regulatinggene expression, cell differentiation, DNA repair, and
neural development1. Disruption of the BAF complex has been
linked to several neurodevelopmental syndromes, commonly
referred to as BAFopathies. Among these are Cofﬁn–Siris and
Nicolaides–Baraitser syndromes (CSS and NCBRS), two pheno-
typically similar genetic conditions characterized by develop-
mental delay and intellectual disability (DD/ID), coarse facial
features, and phalangeal abnormalities2–5. CSS is genetically
heterogeneous and, to date, mutations in more than nine genes
have been demonstrated to cause CSS or a CSS-like phenotype.
The products of all of these genes are either immediate members
of the BAF complex, i.e., ARID1B, ARID1A, SMARCB1,
SMARCA4, SMARCE1, ARID2, and DPF26,7, or interact with it
in the downstream pathways, i.e., SOX11 and PHF64,8. NCBRS is
caused by mutations in SMARCA2, encoding another subunit of
the BAF complex3.
Disruption of the BAF complex in CSS/NCBRS may impact
DNA methylation by two mechanisms. The ﬁrst is through a
direct interaction between chromatin remodeling and DNA
methylation during epigenetic reprogramming9. The BAF com-
plex has been shown to inﬂuence the establishment of DNA
methylation either directly (by recruiting DNA methylases) or
indirectly (by altering expression of proteins that regulate DNA
methylation)10,11. Alternatively, downstream pathways aberrantly
impacted by disruption of the complex may result in speciﬁc
DNA methylation patterns during development12. Therefore, we
hypothesized that CSS and NCBRS might be associated with
speciﬁc germ-line DNA methylation proﬁles in the affected
individuals.
We have previously described peripheral blood DNA methy-
lation signatures in multiple neurodevelopmental syndromes
resulting from defects in various layers of the epigenetic
machinery13–17, including those involving abnormalities in
chromatin remodeling, e.g., Kabuki syndrome18. Through these
reports, we have also shown that DNA methylation signatures
can be used as surrogate markers for molecular diagnostics and
disease screening, with performances superior to sequence variant
analysis14–18. Development of similar approaches may be useful
for diagnosing BAFopathies including CSS and NCBRS, in which
phenotypic/genotypic heterogeneity hinders clinical/molecular
diagnosis.
In the present study, we examine a cohort of CSS/NCBRS
patients with mutations in ARID1B (CSS type 1 (CSS1)),
SMARCB1 (CSS type 3 (CSS3)), SMARCA4 (CSS type 4 (CSS4)),
and SMARCA2 (NCBRS). We describe a DNA methylation sig-
nature shared across all of these groups, providing functional
evidence linking different subtypes of CSS with NCBRS. We show
that this proﬁle is speciﬁc to CSS/NCBRS and does not occur
across other syndromic DD/ID conditions. As well, we demon-
strate that chromosome 6q25 microdeletion syndrome, harboring
AR1D1B deletion, encompasses a proﬁle falling within the CSS/
NCBRS spectrum. Using this proﬁle, we build a classiﬁcation
algorithm for CSS/NCBRS and demonstrate its ability to resolve
ambiguous clinical cases as well as to identify previously
undiagnosed subjects through targeted screening of a large cohort
of undiagnosed patients with DD/ID.
Results
CSS/NCBRS exhibit a DNA methylation epi-signature spec-
trum. We generated genome-wide methylation data using Inﬁ-
nium methylation arrays from peripheral blood DNA of subjects
with both conﬁrmed clinical and molecular diagnosis of CSS/
NCBRS. Following quality controls, 399,329 CpG sites (probes)
were retained for analysis. Comparisons were performed sepa-
rately between patients with CSS1 (n= 14), CSS3 (n= 5), CSS4
(n= 2), and NCBRS (n= 7) with age-matched cohorts of con-
trols with a sample size six times larger than each group (Table 1).
We identiﬁed three probe-sets of 146, 135, and 356 CpG sites
with a minimum 10% methylation difference, and a multiple-
testing corrected p value < 0.05 (limma multivariable regression
modeling), adjusted for blood cell type compositions, for CSS1,
CSS3, and NCBRS, respectively (Supplementary Data 1–3). No
CpG site met these statistical cut-offs in individuals with CSS4
due to insufﬁcient sample size (n= 2). A nominal overlap of
10–20% was observed across the three sets. To examine the extent
to which these three probe-sets were speciﬁc to every subtype, we
performed three separate hierarchical clustering analyses. The
ﬁrst clustering, using probes speciﬁc to CSS1, completely sepa-
rated all of the patients, i.e., CSS1, CSS3, CSS4, and NCBRS, from
the controls, with little distinctions across different subtypes
(Fig. 1a). The second clustering using the CSS3 probes generated
a similar pattern, although it assigned an intermediate cluster to
the entire non-CSS3 patients who represented slightly less pro-
nounced methylation changes (Fig. 1b). The NCBRS-speciﬁc
probes, however, grouped NCBRS and CSS3 into one cluster and
CSS1 and controls into the other. The two CSS4 subjects were
split between the two clusters (Fig. 2). To assure that these
observations are not the result of a general DD/ID methylation
pattern or batch effect, a random mix of non-CSS/NCBRS sub-
jects having other forms of DD/ID, assayed on the same batch as
the patients, were included in each clustering—none grouped
with the CSS/NCBRS samples (Supplementary Figure 1).
These observations indicated that the identiﬁed probes are not
entirely speciﬁc to every BAF subunit and a spectrum of
methylation change is shared across different subtypes. To
investigate the intra-subtype variability and identify subgroups
within these proﬁles, a consensus clustering analysis was
performed on all 29 CSS/NCBRS cases, excluding the controls,
using the combination of the identiﬁed probes. Following 1000
clustering iterations on 80% subsampling of both probes and
subjects at cluster counts (k) ranging from 2 to 10, k= 2 was
found to be the most optimal k with the lowest proportion of
ambiguous clustering (PAC) measure19. This framework gener-
ated two distinct clusters, both with consensuses >0.99 (Fig. 3,
Supplementary Figures 2–18). The ﬁrst cluster was composed of
CSS1 subjects, whereas the second cluster grouped patients with
CSS3 and NCBRS. The two CSS4 subjects were split between the
two clusters. Further iterations at k > 2 did not reﬁne the
separation of the four subtypes. Only at k= 7, the CSS3 patients
separated from the NCBRS cohort, at which point the ﬁrst cluster
(CSS1) was subdivided into four groups (Fig. 3, Supplementary
Figures 2–18). This suggested that variations among CSS1 subjects
are greater than the differences between CSS3 and NCBRS,
indicating that while CSS3 and NCBRS have the most similar epi-
signatures, they contain methylation changes not present in CSS1
(Fig. 3, Supplementary Figures 2–18). Repeat analyses individu-
ally on each of the three probe-sets led to similar observations.
We also ensured that the observed patterns are not generated by a
bias from differences in the sample sizes or probe counts across
the three subtypes (Supplementary Figures 19–21).
Differentially methylated regions in CSS/NCBRS. The identi-
ﬁed probes in the three sets showed a trend towards co-
occurrences within genes (Supplementary Data 1–3). Probes
found in such genes in one of the three sets were also present to
variable degrees in the others (Supplementary Data 1–3). An
example includes three probes in the PALM gene
(chr19:728040–728385), identiﬁed to be hypermethylated in both
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CSS1 and CSS3, two of which were also detected to be hyper-
methylated in NCBRS (Supplementary Data 1–3). This led us to
systematically map differentially methylated regions (DMRs)
across the three subtypes and examine the inter-class variations in
methylation levels. Using the DMRcate algorithm20 we found a
total of 3, 30, and 24 DMRs with a minimum of three consecutive
probes no more than 1 kb apart, >10% average methylation
change, and a false discovery rate (FDR) < 0.05 in CSS1, CSS3,
and NCBRS, respectively (Supplementary Data 4). Among the
three DMRs found in CSS1, a hypermethylated region in
chr12:53,343,514–53,343,849, overlapping the KRT8 promoter
and KRT18 gene body (Fig. 4), met all of the speciﬁed cut-offs in
all three groups. The other two DMRs in CSS1, although not
always reaching the strict cut-offs applied, showed very similar
methylation levels in other subtypes (Fig. 5). Almost all of the
regions found in CSS3 showed an intermediate pattern in the
others, with methylation values between the controls and CSS3
(Supplementary Figure 22). The DMRs found in NCBRS repre-
sented the greatest deviation from methylation levels in CSS1
patients, but a striking similarity to those in CSS3 (Figs. 4, 6).
Shared functionality in the CSS/NCBRS proﬁles. To assess what
is functionally represented in the methylation proﬁles, three
separate gene-set enrichment analyses were performed for each
probe-set. We found 1, 34, and 13 enriched Gene Ontology (GO)
terms (FDR < 0.05) for the probe-sets speciﬁc to CSS1, CSS3, and
NCBRS, respectively (Supplementary Data 5). The single GO
term found in CSS1 was anatomical structure morphogenesis.
The GO terms in CSS3 were composed of biological cell regula-
tions, locomotion, synapse maturation, embryonic organ devel-
opment, and regulation of the mitogen-activated protein kinase
cascade. The GO terms in NCBRS were mainly related to
anatomical structure development and morphogenesis (Supple-
mentary Data 5, Fig. 7). This indicated that gene networks
involved in system development and morphogenesis are repre-
sented across all three probe-sets. To improve the power in GO
term identiﬁcations, the three probe-sets were combined, and the
analysis was repeated. We found 191 GO terms composed of
anatomical and system development, as the most signiﬁcant
terms, followed by various forms of signaling and cellular process
regulations (Supplementary Data 6 and Supplementary
Figure 23).
A classiﬁcation model for CSS/NCBRS. These analyses suggest
that CSS/NCBRS is associated with a methylation proﬁle which
could potentially be used for screening and diagnostic purposes.
Due to a signiﬁcant level of overlap across various CSS/NCBRS
groups, we hypothesized that modeling the differences between
all CSS/NCBRS patients and controls would provide the greatest
power at both stages of feature selection and training. Therefore,
data from all 29 patients were combined and randomly divided
into two cohorts of training (75% subset, n= 21) and testing
(25% subset, n= 8), ensuring that different subtypes are equally
represented in both data subsets (Table 1). A sample of 126 age-
matched controls (six times larger than the patient cohort) was
added to the training subset for the purposes of feature selection
and training. Using moderated p values obtained from the mul-
tivariate regression modeling, we prioritized the top 1000 probes
that were not confounded by batch effect or blood cell type
compositions and showing a minimum 5% detectable methyla-
tion change. Feature selection was performed from this list by ﬁrst
measuring the area under the receiver operating characteristic
curve (AUC) for every probe to select the most differentiating
CpGs (AUC > 0.85), and next by removing the redundant features
Table 1 Patients with a conﬁrmed diagnosis of CSS/NCBRS
ID Disease subtype (gene) Nucleotide changea Variant effect Protein change Data subset
MS0674 CSS1 (ARID1B) c.3444C>G Nonsense p.Tyr1148* Training
MS0676 CSS1 (ARID1B) c.3236delT Frame-shift p.Phe1079Serfs*51 Training
MS0678 CSS1 (ARID1B) c.3716delC Frame-shift p.Pro1239Hisfs*5 Training
MS0680 CSS1 (ARID1B) c.2457dupT Frame-shift p.Pro819fs* Training
MS1169 CSS1 (ARID1B) c.1259delA Frame-shift p.Asn420Ilefs*10 Training
MS1170 CSS1 (ARID1B) c.5605C>T Frame-shift p.Gln1869* Training
MS1176 CSS1 (ARID1B) c.2692C>CT Frame-shift p.Arg898* Training
MS1177 CSS1 (ARID1B) c.3223C>CT Frame-shift p.Arg1075* Training
MS1212 CSS1 (ARID1B) c.3898C>T Nonsense p.Gln1300* Training
MS1216 CSS1 (ARID1B) c.1483C>T Nonsense p.Gln495* Training
MS1201 CSS1 (ARID1B) c.1259delA Frame-shift p.N420Ifs*10 Testing
MS1213 CSS1 (ARID1B) c.1701del Frame-shift p.Ala569Profs*21 Testing
MS1215 CSS1 (ARID1B) c.3352_3359dup Frame-shift p.Met1120Ilefs*53 Testing
MS1217 CSS1 (ARID1B) c.3478delG Frame-shift p.Glu1160Argfs*51 Testing
MS0679 CSS3 (SMARCB1) c.1091_1093delAGA In-frame deletion p.Lys364del Training
MS0683 CSS3 (SMARCB1) c.1130G>A; Missense p.Arg377His Training
MS1162 CSS3 (SMARCB1) c.1121G>A Missense p.Arg374Gln Training
MS0681 CSS3 (SMARCB1) c.1130G>A; Missense p.Arg377His Testing
MS1163 CSS3 (SMARCB1) c.1096C>T Missense p.Arg366Cys Testing
MS1168 CSS4 (SMARCA4) c.1452_1453delGGinsA Frame-shift p.Asp485Ilefs*16 Training
MS1209 CSS4 (SMARCA4) c.2932C>G Missense p.Arg978Gly Training
MS1160 NCBRS (SMARCA2) c.2639C>T Missense p.Thr880Ile Training
MS1221 NCBRS (SMARCA2) c.3602C>T Missense p.Ala1201Val Training
MS1223 NCBRS (SMARCA2) c.3476G>T Missense p.Arg1159Leu Training
MS1238 NCBRS (SMARCA2) c.2642G>T Missense p.Gly881Val Training
MS1243 NCBRS (SMARCA2) c.3404T>C Missense p.Leu1135Pro Training
MS1222 NCBRS (SMARCA2) c.3485G>A Missense p.Arg1162His Testing
MS1237 NCBRS (SMARCA2) c.3475C>G Missense p.Arg1159Gly Testing
aAll mutations are in heterozygous state; mean age of CSS1 subjects (n= 14): 12.0 ± 7.5, matched controls (n= 84): 13.0 ± 9.7; mean age of CSS3 subjects (n= 5): 3.0 ± 3.9, matched controls (n= 30):
3.0 ± 3.3; mean age of NCBRS subjects (n= 7): 11.5 ± 11.3, matched controls (n= 42): 11.9 ± 11.2; mean age of patients in the training dataset (n= 21): 9.3 ± 8.5, matched controls (n= 126): 10.0 ± 8.6
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with a pairwise correlation coefﬁcient >0.85. The ﬁnal probe-set
(n= 131, Supplementary Data 7) was used to train a support
vector machine (SVM) with radial basis function kernel on the
training cohort. The model was set to generate a score ranging
0–1, representing the probability of a given sample having a
methylation proﬁle similar to CSS/NCBRS. A 10-fold internal
cross-validation was performed during the training process,
which resulted in an accuracy of 98.8% (model details in Sup-
plementary Data 7).
To control for the success of the training procedure, the entire
training cohort was supplied to the ﬁnal model, which assigned
correct classiﬁcations to all of the cases (scored >0.90) and
controls (scored <0.10) used for training (Fig. 8). Next, we
conﬁrmed that the model could completely differentiate the non-
CSS/NCBRS samples assayed on the same technical batch of the
cases (n= 244) from the true CSS/NCBRS samples by supplying
their methylation values into the model for prediction. None of
these samples were scored high for CSS/NCBRS, indicating the
trained model is not sensitive to the batch structure of the data.
Additionally, we evaluated the extent to which this model is
sensitive to variations in blood cell type compositions by applying
it to a total of 60 methylation array data ﬁles from six healthy
individuals, downloaded from gene expression omnibus (GEO,
GSE35069)21, each being assayed for whole blood, peripheral
blood mononuclear cells, and granulocytes, as well as for seven
isolated cell populations (CD4+ T, CD8+ T, CD56+ natural
killer cell, CD19+ B, CD14+ monocytes, neutrophils, and
eosinophils), separately. All of these samples were classiﬁed as
a
Beta value
b
CSS/NCBRS
Non-CSS/NCBRS
Control
CSS4
NCBRS
CSS1
CSS3
0 0.2 0.4 0.6 0.8
Fig. 1 Clustering analysis using the probe-sets identiﬁed in CSS1 and CSS3. Clustering analysis was performed using Ward’s method on Euclidian distance.
Rows represent the CpG probes, and columns represent the subjects. The color scale from dark blue to dark red represents the range of the methylation
levels (beta values) between 0 and 1. The top pane represents the overall status of the condition, i.e., CSS/NCBRS vs. non-CSS/NCBRS. The lower pane
indicates the subtype for every sample including CSS1 (dark blue), CSS3 (dark green), CSS4 (orange), NCBRS (light green), and controls (yellow).
a Hierarchical clustering of 146 probes differentially methylated between patients with CSS1 and controls generates two clusters: one composed of all CSS
and NCBRS patients (CSS1, CSS3, CSS4, and NCBRS), and the other composed of controls and other non-CSS/NCBRS samples. b A similar pattern is
observed using the 135 probes that were speciﬁcally identiﬁed for the CSS3 samples; however, patients other than CSS3 (CSS1, CSS4, and NCBRS) show a
less pronounced pattern of methylation change, although still being a member of the same CSS3 cluster
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non-CSS/NCBRS with scores ranging 0.01–0.13, consistent with
those generated for the whole blood samples. The average inter-
cell-type variability in the scores was determined to be not more
than 10% (Supplementary Data 8).
Next, we applied the model to the CSS/NCBRS samples in the
testing cohort, composed of 8 subjects (4 CSS1, 2 CSS3, and 2
NCBRS) who were not used for feature selection or model training.
All of these samples were scored >0.90 (Fig. 8), conﬁrming that the
model can detect the affected subjects. To measure the speciﬁcity of
our classiﬁer, we tested 122 healthy subjects with various racial
backgrounds (aged 0–36 years) from our internal dataset, combined
with two publically available whole blood methylation cohorts from
healthy subjects, downloaded from GEO, including 48 children
aged 6–14 years (GSE104812)22, and 186 adults aged 25–67 years
(GSE67705)23. All of these 356 healthy subjects received very low
scores (<0.2) for CSS/NCBRS (Fig. 8). We also questioned whether
the model could differentiate the CSS/NCBRS patients from other
forms of DD/ID or other Mendelian conditions that result from
defects in the epigenomic machinery. DNA methylation proﬁles of
a total of 531 subjects diagnosed with 20 different such syndromic
conditions (details in Methods) were supplied to the model for
classiﬁcation, all of which were scored very low for CSS/NCBRS,
suggesting that the proﬁle of CSS/NCBRS does not overlap with
other DD/ID syndromes.
Due to the relatively small sample sizes and incomplete
distinctions across various CSS/NCBRS subtypes, as well as lack
of data on other genes involved, a supervised stratiﬁcation of
BAFopathoies into their subtypes was not possible. However, for
clinical purposes, it is desirable to pinpoint the causative genes.
To this end, any subject that was predicted using our classiﬁcation
model to be a case of CSS/NCBRS was also assessed using the
consensus clustering analysis (Fig. 3) to determine which of the
two previously identiﬁed clusters (CSS1 vs. CSS3-NCBRS) the
sample segregates with, enabling us to further narrow down the
genetic etiology.
Chr6q25 microdeletion syndrome and CSS/NCBRS proﬁle.
We, ﬁrst, used the classiﬁcation model to assess four subjects with
chromosome 6q25 microdeletion syndrome (Table 2). This
condition results from variable length deletions in the interstitial
region of the long arm of chromosome 6 in different individuals.
The shortest of these was recently mapped in one patient to a 1.1
Mb region containing only the ARID1B gene24. Despite the
suggestion that ARID1B is the key gene in this syndrome, clinical
presentations are not entirely similar to CSS and tend to diverge
as the deletion coordinates varies. Our model assigned scores
>0.95 (Fig. 8) to all four patients with Chr6q25 deletion syndrome
(deletions ranging 3.7–13.8 Mb in size, all overlapping ARID1B),
suggesting that this syndrome falls within the spectrum of the
CSS/NCBRS methylation proﬁle. With the initial assumption that
haploinsufﬁciency of ARID1B generates a pattern similar to CSS1,
we assessed these patients using the consensus clustering. In
contrast to our expectation, we observed that only the sample
with the shortest deleted segment (3.7 Mb) was assigned to the
CSS1 cluster, while the rest were clustered with the CSS3-NCBRS
group (Table 2). This indicates that as the size of the deletion is
increased, the subjects may obtain additional methylation chan-
ges not present in CSS1. It may also suggest that the methylation
proﬁle spectrum of BAFopathies is not completely stratiﬁed by
the causative genes.
Classiﬁcation of cases with uncertain CSS/NCBRS diagnosis.
To evaluate the utility of this model in clinical molecular diag-
nostics, we attempted to classify a total of 18 subjects for whom
the diagnosis was uncertain/unconﬁrmed or who carried variants
of unknown clinical signiﬁcance (VUS) in a CSS/NCBRS-related
gene (Table 2). We ﬁrst tested two subjects with clinical suspicion
for CSS, one carrying a de novo VUS in ARID1B (c.5833T>C, p.
Cys1945Arg) and the other one with no sequence data available at
the time of assessment. Both of these patients were predicted to
have CSS/NCBRS by our model (scored 0.88 and 0.94) and were
assigned CSS1 category by the consensus clustering. In silico
analysis of the missense variant in the ﬁrst patient revealed that it
is conserved at both nucleotide and amino acid levels, located in
an evolutionarily conserved gene segment, and is not found in
any public genetic variant database, complying with our
CSS/NCBRS
Non-CSS/NCBRS
Control
CSS4
NCBRS
CSS1
CSS3
Beta value
0 0.2 0.4 0.6 0.8
Fig. 2 Clustering analysis using the probes identiﬁed for NCBRS. Clustering analysis was performed using Ward’s method on Euclidian distance. Rows
represent the CpG probes, and columns represent the subjects. The color scale from dark blue to dark red represents the range of the methylation levels
(beta values) between 0 and 1. The top pane represents the overall status of the condition, i.e., CSS/NCBRS vs. non-CSS/NCBRS. The lower pane indicates
the subtype for every sample including CSS1 (dark blue), CSS3 (dark green), CSS4 (orange), NCBRS (light green), and controls (yellow). Hierarchical
clustering of 365 probes differentially methylated between patients with NCBRS selectively groups CSS3 and NCBRS samples into one cluster, but CSS1
and controls into the other. The two CSS4 subjects are split between the two clusters
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prediction. Targeted exome sequencing of ~4600 Mendelian
genes, including ARID1A, ARID1B, ARID2, SMARCB1,
SMARCA4, and SMARCA2 in the second subject, identiﬁed an in-
frame duplication in ARID1A (c.6507_6509dup), not reported in
any public variant database. While this variant remains to be of
unknown signiﬁcance, the involvement of other CSS-related
genes cannot be completely ruled out.
Next, we evaluated one subject with a VUS in SMARCA2
(c.2647C>G, p.Pro883Ala) at a codon in which alternative amino
acid changes were known to cause NCBRS. This patient was
considered to be a good clinical match for NCBRS, scored 0.83 by
our model, and was assigned to the CSS3-NCBRS class by the
consensus clustering. Parental testing later conﬁrmed a de novo
inheritance, leading to a change in the variant classiﬁcation from
VUS to likely pathogenic. Subsequent trials were performed on
two subjects with likely pathogenic variants in SMARCA2, as
determined according to the American College of Medical
Genetics (ACMG) guidelines for classiﬁcation of sequence
variants25, but with no clinical evaluation reports available at
the time of the study. One of these subjects was scored 0.71 and
assigned CSS-NCBRS category. She carried a novel de novo
missense change (c.2261G>C) in a highly conserved nucleotide
which was predicted by multiple in silico assessments to be
deleterious. Subsequent clinical assessments were found in favor
of an NCBRS diagnosis. The second case had a novel de novo
missense change (c.1697C>T). Strict adherence to the ACMG
guidelines resulted initially in a likely pathogenic variant
classiﬁcation (PS2, PM2, and PP2). However, clinical evaluations
demonstrated that the patient does not exhibit features consistent
with NCBRS, and in silico analysis did not conclude a deleterious
effect for the variant. Of interest, this subject was scored <0.01 by
our classiﬁer. This latter ﬁnding was considered as strong
functional evidence for benign variant effect (BS3), which resulted
in downgrading this variant to likely benign.
Finally, we screened 11 subjects with VUSs identiﬁed by
previous ARID1B testing, without any prioritization based on
clinical data. None of these were predicted to have a proﬁle
similar to CSS/NCBRS by our algorithm (Table 2, all scored
<0.05). This ﬁnding is consistent with the fact that non-
truncating variants in ARID1B are rarely pathogenic in CSS.
Also, we tested two subjects, with missense VUSs in ARID1A,
both of which were scored low by our model (0.06 and 0.17). We
did not have a CSS case resulting from ARID1A mutations in our
training dataset, and thus cannot assume a conﬁdent prediction
on subjects carrying ARID1A variants. However, most pathogenic
ARID1A variants in CSS are truncating, the two patients tested
did not have a typical presentation of CSS, and both of the
reported variants are present in public databases with allele
frequencies >0.0001. Therefore, our model predictions for these
two subjects seem to be consistent with the available information.
Targeted screening of undiagnosed DD/ID patients. Next, we
addressed the utility of this model as a screening method for
identiﬁcation of new CSS/NCBRS cases in a targeted population.
We applied the algorithm to a total of 508 samples from indivi-
duals affected by various forms of DD/IDs, dysmorphic facial
features, and other miscellaneous clinical ﬁndings, but without a
conclusive clinical/molecular diagnosis. From this cohort, our
model classiﬁed two subjects as CSS/NCBRS with scores 0.98 and
0.86 (Fig. 8). The ﬁrst subject clustered with the CSS1 group,
while the other was assigned a CSS3-NCBRS cluster by the
consensus clustering. Evaluations of the medical records identi-
ﬁed the ﬁrst case as a 6-year-old male presenting with global
developmental delay, coarse facial features, ﬂattened nose, sparse
hair, ﬁrst ﬁnger clinodactyly, mild ptosis, and seizures. Brain
imaging identiﬁed a Chiari malformation Type I. Subsequent
exome sequencing identiﬁed two frame-shift mutations in
ARID1B in close proximity (c.5151del and c.5153del), both
resulting in a premature stop codon in the 48th amino acid
downstream of the mutation (p.Lys1718Argfs*48). These muta-
tions together accounted for 50% of the sequencing reads (33%
and 16% each), suggesting a heterozygous mosaic status, which
was later supported by Sanger sequencing. The mutation
screening combined with the clinical phenotype assessment
conﬁrmed this patient’s diagnosis of CSS1. The second subject
was a 2-month-old male with small hands and ears, hypospadias,
and asymmetry of palpebral ﬁssures. Chromosomal microarray
testing was normal and sequence variant analysis of ~4600
clinically relevant genes, including ARID1A, ARID1B, ARID2,
SMARCB1, SMARCA4, and SMARCA2, did not identify a pos-
sible causative variant. Analysis of indels and copy number var-
iations, obtained from the exome data, also did not ﬁnd a
pathogenic event in a gene known to cause a DD/ID condition.
These observations indicated that our method could be applied to
screening and identiﬁcation of undiagnosed cases of CSS/NCBRS
or to suggest a diagnosis when a causative sequence variant
cannot be identiﬁed by standard gene sequencing.
Discussion
Since the report of the Cofﬁn–Siris syndrome in 19702, evidence
has accumulated to consider BAFopathies as a continuum. This
was ﬁrst established by the clinical similarity, next by a shared
genetic etiology, and here by identiﬁcation of overlapping DNA
methylation signatures. The two BAFopathies presented here,
CSS and NCBRS, constitute a phenotypic continuum with
roughly deﬁned separation. Both syndromes represent DD/ID,
sparse hair, dysmorphic facial features, seizures, and phalangeal
abnormalities. The main distinction between them is made by the
distal limb features5–8. Typical NCBRS patients represent pro-
minent interphalangeal joints and distal phalanges, whereas CSS
cases mainly show hypoplasia/aplasia of the ﬁfth ﬁngers/ﬁnger-
nails26. However, such distal limb abnormalities are variably
presented among the patients, ranging from a complete absence
of the ﬁfth ﬁnger in some CSS patients with ARID1A mutations
to only ﬁngernail hypoplasia in the others27. Notably, in up to
25% of the CSS cases, no distal limb abnormality is observed27.
Similarly, while not all NCBRS cases present with prominent
interphalangeal joints, this hallmark of NCBRS is found in some
CSS3 and CSS4 subjects28. As a result, CSS and NCBRS cases
have been frequently diagnosed as one another4,29. Recently, two
cases with duplications of SMARCA2 were described whose
phenotypic features more closely resembled CSS rather than
NCBRS30. Wieczorek et al.4, following a comprehensive mole-
cular and clinical assessment of CSS and NCBRS, reported that
some of the patients represented an intermediate phenotype
between CSS and NCBRS, proposing that these syndromes may
represent a disease spectrum rather than two distinct disorders.
Our ﬁndings are consistent with these reports. We showed that
the DNA methylation proﬁle identiﬁed in CSS1 differentiates not
only CSS1 subjects, but also CSS3, CSS4, and NCBRS cases from
controls, suggesting a shared DNA methylation landscape across
all CSS/NCBRS subtypes. Separate analyses for CSS3 and NCBRS
showed that these two subtypes have additional methylation
changes absent from CSS1, yet they are not easily distinguishable
from each other. This indicates that a stronger similarity can exist
between some CSS subtypes with NCBRS than there is within
CSS. However, DNA methylation alone may not elucidate the
entire functional basis of CSS/NCBRS to allow for uniﬁcation of
the two syndromes. Also, using our retrospective study design, it
is difﬁcult to decipher whether these changes are causal/
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Fig. 4 Two genomic regions differentially methylated in CSS/NCBRS The top panel illustrates three consecutive probes annotating to the promoter of the
KRT8 gene and the ﬁrst and second intron of two isoforms of KRT18. The region is located in a segment highly enriched for H3K27 acetylation, a marker of
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segment. The lower panel depicts a segment upstream NFIA, located in a CpG island shore region with active H3K27 acetylation, potentially an active
promoter. The region is hypomethylated in the CSS3 and NCBRS cases as compared to the controls; however, no difference is observed between CSS1 and
controls for this segment. It is noticeable that one of the two CSS4 subjects shows a hypomethylation pattern similar to CSS3 and NCBRS, whereas the
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consequential, or determine at what stage they occur during the
cascade of events happening between the dysfunction of the BAF
complex and establishment of the neurodevelopmental pheno-
types. Since the observed changes are small in effect size and are
restricted to <0.1% of the entire CpGs tested across the genome, it
is unlikely that they represent any fundamental event at the
single-gene regulatory level or during epigenomic
reprogramming.
Notwithstanding, the identiﬁed methylation changes occur in
genes that are highly enriched in developmental, morphogenesis,
and regulatory pathways. In particular, the proﬁle contains
multiple CpGs located in the genes involved in cell signaling and
neural differentiation. One example is the PALM gene which
encodes a member of the Paralemmin protein family involved in
plasma membrane dynamics in neurons31. A second example is
the KRT8 promoter (Fig. 4), the most consistently differentially
methylated region in this study (hypermethylated in all CSS/
NCBRS subjects). KRT8 is a type II keratin family member which
acts as an intermediate ﬁlament in epithelial cells and plays a role
in maintaining the integrity of the cell structure, signal trans-
duction, and cellular differentiation32. Also, the overall pattern of
the epi-signatures seems to be consistent with the phenotypic
variations across CSS/NCBRS. CSS3 patients represent the most
severe form of the disease, whereas CSS1 cases typically exhibit
the milder end of the spectrum and often have normal
growth4,27,33. Consistent with this, we observed that the majority
of shared methylation components across CSS/NCBRS are most
exaggerated in CSS3, while methylation changes observed in
CSS1 seem to harbor the most moderate effect sizes of all. Of
interest, the DNA methylation similarity between CSS3, NCBRS,
and one of the CSS4 subjects may correlate with the occasional
occurrence of interphalangeal joint prominence in NCBRS, CSS3,
and CSS4, but not in CSS1. These phenotypic correlations toge-
ther with the over-representation of the developmental biological
processes in the methylation signatures can reﬂect the more
downstream biological pathways that might be inﬂuenced by a
disruption of the BAF complex1.
While the degree of overlap in the epi-signatures extends
beyond CSS/NCBBRS to Chr6q25 microdeletion syndrome, the
observed changes remain to be limited to BAFopathies and do not
occur in a similar pattern in other neurodevelopmental disorders
or those conditions caused by defects in other epigenetic reg-
ulators. Different histone modifying enzymes are known to affect
shared pathways which might result in overlapping epigenetic
changes across the chromatin-related disorders. We addressed
this issue in CSS/NCBRS by supplying methylation values from a
large cohort of such conditions (n= 531) to our classiﬁcation
model. All of these subjects received very low scores for CSS/
NCBRS, suggesting that despite overlapping targets in the histone
modiﬁers, the downstream changes are unique to each condition,
indicating that the DNA methylation signature of CSS/NCBRS
could have an invaluable clinical utility.
We took advantage of these ﬁndings and developed a classiﬁ-
cation tool to be used for clinical diagnosis and screening. Using
multiple external and internal datasets we conﬁrmed that our
model is completely speciﬁc to CSS/NCBRS, and its performance
is not inﬂuenced by variations in sex, age, ethnicity, and blood cell
type compositions, or does not falsely detect other developmental
conditions. The rarity of CSS and NCBRS (~200 CSS and ~100
NCBRS cases reported worldwide—considered to be an under-
estimate)28,34, overlapping clinical features with other conditions,
and non-speciﬁc presentations limit the clinical detection of these
syndromes. The CSS1 patient we identiﬁed through targeted
screening had remained undiagnosed for years, despite having a
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relatively typical presentation of the syndrome. Notably, he did
not have hypoplasia of the ﬁfth ﬁnger, a clinical hallmark for CSS
diagnosis. Such a diagnosis is further challenged by the fact that
DNA sequence analysis cannot always provide a conclusive result.
For roughly 40% of the CSS cases reported in the literature, a
molecular diagnosis has not been established28,34. While some of
these patients might carry mutations in yet-to-be identiﬁed genes,
others carry VUSs, or variants not sequenced in routine screen-
ing, such as large indels or noncoding variants. We demonstrate
that DNA methylation proﬁling provides a powerful solution to
these challenges. When a non-CSS/NCBRS classiﬁcation is made
for a subject with a VUS, this tool can conﬁdently rule out a
deleterious effect for the suspected variant. An example was the
subject with a de novo missense variant in SMARCA2 (Table 2),
where strict adherence to the variant classiﬁcation system had
resulted in a likely pathogenic classiﬁcation. This patient was
found later to not show either the clinical features or the
methylation proﬁle consistent with NCBRS, indicating that the
reported variant was benign and sequence variant assessment
alone without consideration of clinical and functional data can
sometimes be misleading. It is worthwhile, however, to note that a
CSS/NCBRS classiﬁcation may not necessarily indicate a patho-
genic effect for a variant, since unreported sequence variants may
be responsible for the methylation signature. Additionally, we
showed that our method could diagnose BAFopathy cases, for
whom a causative variant cannot be found, a very common
phenomenon in CSS28,34. We propose that genomic DNA
methylation assessment has a potential to become part of
the clinical screening of patients with broad ranges of develop-
mental disorders, taking into consideration that, in addition to
BAFopathies, it allows for concurrent assessment of multiple
syndromes resulting from DNA methylation defects,
including imprinting conditions35, Fragile X syndrome36, and
other previously described conditions with epi-signatures17.
Given the cost of DNA methylation microarray testing is similar
to the cost of a single-gene test, it has a potential to be adapted in
molecular diagnosis together with current genomic screening
tests.
Alongside unraveling the functional continuum and diagnostic
utility of an epigenetic signature in BAFopathies, our ﬁndings
generate new questions to be explored by further research. We
have not investigated whether the observed changes are present in
other organs, particularly in the neural tissue, the main source of
involvement in BAFopathies. A previous study has shown that a
hypomethylation proﬁle detected in the blood of the Sotos syn-
drome can also be found in the ﬁbroblasts of the patients; yet, this
might not be the case for BAFopathies. In addition, the impact of
the observed methylation signatures on the pathology of the
disease is unknown. These may involve integrative investigation
of gene expression changes and histone modiﬁcation patterns
among the affected individuals. Animal models to study devel-
opment can reveal the origin of the changes and potentially shed
light on the pathways involved in pathogenesis. Other less com-
mon gene mutations associated with BAFopathies will need to be
investigated. With more samples it may be possible to examine
differences in methylation patterns across different mutation
types, e.g., loss vs. gain of function, and different genes encoding
different proteins of the BAF complex.
DNA methylation testing in unsolved DD/ID cohorts has
signiﬁcant potential, in conjunction with sequence variant ana-
lysis, to enable new molecular diagnoses. Gene sequencing is
expected to remain the gold standard for the diagnosis of Men-
delian conditions; however, in many cases, it will need to be
augmented with functional evidence. Similarly, description of
Mendelian diseases and delineation of the phenotypes will be
inﬂuenced by the functional data. This report presents an
example of how functional evidence, obtained through high-
throughput epigenomic and computational approaches, can
change our understanding of human disease and provide us with
more efﬁcient tools for screening and diagnosis.
Macromolecule modification
Cellular response to stimulus
Regulation of MAPK cascade
Lamellipodium assembly
Wound healing
Intracellular signal transduction
Positive regulation of cellular component biogenesis
Positive regulation of biological process
Positive regulation of cellular process
Developmental process
Synapse maturation
Cardiovascular system development
Stem cell population maintenance
Maintenance of cell number
Sensory organ development
Embryonic organ development
System development 
Fig. 7 Gene ontology terms enriched in the CSS/NCBRS methylation proﬁle. The ﬁgure is generated from a reduced list (redundant GO terms have been
removed) of the entire 58 GO terms found to be signiﬁcantly enriched, separately, in the three probe-sets related to CSS1, CSS3, and NCBRS
(Supplementary Data 5). The color intensity represents the degree of signiﬁcance (p value obtained from a hypergeometric test conducted by missMethyl
package). The size of each circle indicates the number of GO terms it was related to before the reduction of the redundant terms was performed. The
thickness of the connecting lines corresponds to the level of interactions and relatedness among the pathways. System development followed by regulation
of cellular process represent the most signiﬁcant GO terms in this analysis. Visualization of the 192 GO terms, found after combining the three probe-sets
(Supplementary Data 6), is illustrated in Supplementary Figure 23
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Methods
Patients and cohorts. Peripheral blood DNA samples from patients with CSS
were collected from the Greenwood Genetic Center (Greenwood, SC, USA),
London Health Sciences Center (London, ON, Canada), and Care4Rare Canada
Consortium (CHEO Research Institute, Ottawa, ON, Canada). Subjects diagnosed
with NCBRS were recruited from the Department of Pediatrics at the University of
Amsterdam (Amsterdam, The Netherlands). These cases were previously described
in detail by Van Houdt et al.3. Patients with Chr6q25 deletion syndrome were
recruited from Baylor College of Medicine (Houston, TX, USA), previously deli-
neated clinically/molecularly in detail by Nagamani et al.37.
Control subjects were selected from our laboratory reference cohort that is
composed of individuals without any abnormal imprinting defects or known
diseases that inﬂuence the epigenomic proﬁle. This reference cohort was previously
preselected from a larger cohort of approximately 1000 individuals across a broad
range of age, sex, and ethnicity distribution. The validation cohort, which was later
used to measure the speciﬁcity of our algorithm, is composed of healthy individuals
collected from the Greenwood Genetic Center, and two publically available
databases obtained from GEO (GSE67705 and GSE104812)22,23.
Samples from patients with other diagnosed DD/ID conditions were collected
from Greenwood Genetic Center and Care4Rare Canada Consortium. Patients
with Angelman syndrome, Prader–Willi syndrome, Beckwith–Wiedemann
syndrome, Sotos syndrome, Claes–Jensen syndrome, CHARGE syndrome, Kabuki
syndrome, ATRX, Cofﬁn–Lowry syndrome, Rett syndrome, Fragile X syndrome,
autism spectrum disorders, and RASopathies were recruited from the Greenwood
Genetic Center. Peripheral blood DNA samples from patients with autosomal
dominant cerebellar ataxia with deafness and narcolepsy, Genitopatellar syndrome,
and Floating–Harbor syndrome were collected from the Care4Rare Canada
Consortium. Subjects with trisomy 21 were recruited from McMaster University
Medical Centre (Hamilton, ON, Canada). Samples with Silver–Russell syndrome
were downloaded from GEO (GSE104451 and GSE55491)38,39.
Any subject used herein to represent a condition had a conﬁrmed clinical diagnosis
of the aforementioned syndrome and was screened for mutations in the related genes.
The mutation report from every patient was reviewed according to the ACMG
guidelines for interpretation of genomic sequence variants25, and only individuals
conﬁrmed to carry a pathogenic or likely pathogenic mutation together with the
clinical diagnosis were used to identify an epi-signature or to represent a syndrome.
Samples with uncertain clinical/molecular diagnosis for CSS/NCBRS were
collected from Greenwood Genetic Center, London Health Sciences Center, and
Care4Rare Canada Consortium. Targeted screening was performed in a cohort
composed of patients with DD/ID but with no clinical/molecular diagnosis at the
time of recruitment. These patients have been recruited on an ongoing basis since
2014 from the Department of Pediatrics at McMaster University and London
Health Sciences Centre, to be part of an ongoing project aiming at the development
of a genome-wide DNA methylation testing for DD/ID conditions.
Methylation assay and quality control. Peripheral whole blood DNA was
extracted using standard techniques. Following bisulﬁte conversion, DNA methy-
lation analysis of the samples was performed using the Illumina Inﬁnium
methylation 450k or EPIC bead chip arrays (San Diego, CA), according to the
manufacturer’s protocol. The resulting methylated and unmethylated signal
intensity data were imported into R 3.4.2 for analysis. Normalization was
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Fig. 8 Scores generated for different subjects by the CSS/NCBRS classiﬁcation model. An SVM classiﬁer generates scores for every subject as the
probability of having a DNA methylation proﬁle similar to what is observed in CSS/NCBRS. The y axis represents scores 0–1, with higher scores indicating a
higher chance of carrying a methylation proﬁle related to CSS/NCBRS, as stratiﬁed on the x axis for different groups of tested subjects. Every point
represents a single sample. By default, the SVM classiﬁer deﬁnes a cut-off of 0.5 for assigning the class (dashed line); however, the vast majority of the
tested individuals received a score <0.2 or >0.8. Therefore, to improve visualization, the points are jittered. CSS/NCBRS T: CSS/NCBRS patients from the
training set (n= 21); Control T: control samples used to train the model (n= 126); CSS/NCBRS V: Samples from the testing set (n= 8), who were not used
for feature selection or model training; Control V: healthy subjects from one internal (n= 122) and two external cohorts (n= 48 and 186) used to measure
the speciﬁcity of the model (n= 356); Other syndromes: subjects diagnosed with various syndromic diseases presenting with DD/ID (n= 531, details in
Methods); Chr6q25del: four patients with interstitial deletions in Chr6q25 (Table 2); VUS: subjects with variants of unknown clinical signiﬁcance (VUS) in
a CSS/NCBRS-related gene, or with clinical suspicion for CSS/NCBRS (Table 2); Screening: subjects with various presentations of developmental delay and
intellectual disability, but with no diagnosis, used for case ﬁnding (n= 508). The ﬁrst two categories represent the classiﬁcation of the subjects used to
train the algorithm. The second two validate the performance of the classiﬁcation model on the testing dataset. In the ﬁfth category, the model
demonstrates the ability to accurately distinguish other DD/ID cases from CSS/NCBRS. All of the Chr6q25del patients (sixth category) are scored high for
having a proﬁle related to CSS/NCBRS. The model classiﬁes four of the subjects with VUS or clinical suspicion for CSS/NCBRS as a case of CSS/NCBRS
and assigns non-CSS/NCBRS status to the rest of the subjects in the seventh category. In the last category, screening of a DD/ID cohort identiﬁes two
subjects as a potential case of CSS/NCBRS
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performed using Illumina normalization method with background correction using
the minﬁ package40. Probes with detection p value > 0.01, those located on chro-
mosomes X and Y, those known to contain single-nucleotide polymorphisms at the
CpG interrogation or single-nucleotide extension, and probes known to cross-react
with chromosomal locations other than their target regions were removed. Arrays
with more than 5% failed probe rate were excluded from the analysis. All of the
samples were examined for genome-wide methylation density, and those deviating
from a bimodal distribution were excluded. Factor analysis using a principal
component analysis was performed to rule out batch effect or unexplained varia-
tions. Outliers were identiﬁed in this analysis and removed. No batch effect was
observed by factor analysis. All of the patients and controls clustered together and
did not separate based on the batch variable.
Selection of controls for methylation proﬁling. For every iteration aiming at the
identiﬁcation of the methylation proﬁles or feature selection, a random sample of
controls was selected separately from our reference cohort to be compared with the
case groups. Matching was done by age and array type using the MatchIt package for
every group. The sample size of the controls was increased until both the matching
quality and sample size were at their optimum and consistent across all analyses.
This led to the determination of a control sample size six times larger than the case
groups in every comparison. Increasing the sample size beyond this value impaired
the matching quality. Given the CSS samples were assayed using two different
Inﬁnium arrays (450k and EPIC), we matched the controls to the cases according to
the array type to ensure that our ﬁndings are not confounded by technical variation.
The analyses only considered probes shared by both arrays to maintain consistency
in computational workﬂow and biological interpretability of the ﬁndings.
Identiﬁcation of the CSS/NCBRS-related methylation proﬁles. The analysis
was performed using a modiﬁcation of our previously published protocol13–18,41.
The methylation level for each probe was measured as a beta value, calculated from
the ratio of the methylated signals vs. the total sum of unmethylated and methy-
lated signals, ranging between 0 (no methylation) and 1 (full methylation). This
value was used for biological interpretation and visualization. For statistical ana-
lysis, wherever a normal distribution was required (linear regression modeling),
beta values were logit transformed to M-values using the following equation: log2
(beta/(1−beta)). A linear regression modeling using the limma package42 was used
to identify the differentially methylated probes. The analysis was adjusted for sex
and blood cell type compositions, estimated using the minﬁ package according to
the algorithm developed by Houseman et al.43. The estimated blood cell propor-
tions were added to the model matrix of the linear models as confounding vari-
ables. The generated p values were moderated using the eBayes function in the
limma package and were corrected for multiple testing using the Benjamini and
Hochberg method. Probes with a corrected p value < 0.05 and a methylation dif-
ference greater than 10% were considered signiﬁcant. The effect size cut-off of 10%
was chosen to avoid reporting of probes with low effect size, those inﬂuenced by
technical or random variations, and those not biologically interpretable, as con-
ducted in our previous studies13–18,41.
Clustering analyses. The identiﬁed probes were examined using an unsupervised
hierarchical clustering analysis to ensure their ability in separating the patients from
controls and to examine the similarity between various subtypes of CSS/NCBRS.
Hierarchical clustering was performed using Ward’s method on Euclidean distance by
the gplots package. Consensus clustering was performed using Concensu-
sClusterPlus44 to determine subgroups within CSS/NCBRS proﬁle. This algorithm
identiﬁes clusters by calculating the consensus across multiple runs of a clustering
algorithm and measuring the stability of the clusters. We performed 1000 clustering
analyses using the k-means algorithm on Spearman’s distance following 80% sub-
sampling of both the samples and probes for speciﬁed cluster counts (k) between 2
and 10. The cluster count generating consensus cluster value >0.9 for all of the
identiﬁed clusters and with the smallest PAC measure19 was regarded the optimal k.
Identiﬁcation of the differentially methylated regions. To identify genomic
regions harboring methylation changes (DMRs), the DMRcate algorithm20 was
used. Using the kernel smoothing estimation of the association signals calculated
for every CpG probe across the genome against a null distribution, generated using
the limma regression modeling, DMRcate identiﬁed regions with a minimum of
three probes no more than 1 kb apart and an average regional methylation dif-
ference >10%. We selected regions with a Stouffer transformed FDR values of the
Table 2 Classiﬁcation of subjects with Chr6q25 deletions, with variants of unknown signiﬁcance in a CSS/NCBRS-related gene,
or with a clinical suspicion for CSS/NCBRS
ID Suspected genetic change In silico
assessmenta
Variant
population allele
frequency
Primary ACMG
variant
classiﬁcation
CSS/NCBRS score
(Consensus clustering)b
Support
for
prediction
MS0684c 6q25.2-q.25.3del (3.77Mb) N/A N/A Pathogenic 0.99 (CSS1) N/A
MS0685c 6q25.2-q26del (6.7Mb) N/A N/A Pathogenic 0.98 (CSS3-NCBRS) N/A
MS0686c 6q24.3-q25.3del (10.3 Mb) N/A N/A Pathogenic 0.96 (CSS3-NCBRS) N/A
MS0687c 6q25.2-q27del (13.81 Mb) N/A N/A Pathogenic 0.95 (CSS3-NCBRS) N/A
MS0672d ARID1B (c.5833T>C, p.Cys1945Arg) Deleterious 0 VUS 0.88 (CSS1) h, i
MS1220d ARID1A (c.6507_6509dup, p.Leu2171dup) N/A 0 VUS 0.94 (CSS1) h
MS1227d SMARCA2 (c.2647C>G, p.Pro883Ala) Deleterious 0 VUSg 0.83 (CSS3-NCBRS) h, i, j
MS1185e SMARCA2 (c.2261G>C, p.Gly754Ala) Deleterious 0 Likely pathogenic 0.71 (CSS3-NCBRS) h, i
MS1161e SMARCA2 (c.1697C>T, p.Ala566Val) Conﬂicting 0 Likely pathogenic <0.01 k
MS1188f ARID1B (c.6634C>T, p.Arg2212Cys) Deleterious 0.0001 VUS 0.04 l, m
MS1189f ARID1B (c.725G>C, p.Gly242Ala) Conﬂicting 0 VUS <0.01 l
MS1190f ARID1B (c.1183G>A, p.Ala395Thr) Benign 0 VUS <0.01 l
MS1191f ARID1B (c.1318T>C, p.Tyr440His) Conﬂicting 0.0004 VUS <0.01 l, m
MS1192f ARID1B (c.2414A>G, p.Tyr805Cys) Conﬂicting 0.001 VUS <0.01 l, m
MS1193f ARID1B (c.3583C>T, p.Pro1195Ser) Conﬂicting 0.0004 VUS <0.01 l, m
MS1196f ARID1B (c.504C>A, p.Gly168=) N/A 0.001 VUS 0.01 l, m, n
MS1197f ARID1B (c.5179G>A, p.Asp1727Asn) Conﬂicting 0 VUS <0.01 l
MS1198f ARID1B (c.5510A>G, p.Lys1837Arg) Conﬂicting 0 VUS <0.01 l
MS1199f ARID1B (c.5586A>G, p.Lys1862=) N/A 0.0002 VUS <0.01 l, m, n
MS1200f ARID1B (c.6032A>T, p.Glu2011Val) Deleterious 0 VUS <0.01 l
MS1214f ARID1A (c.1175C>A, p.Pro392His) Deleterious 0.0002 VUS 0.06 l, m
MS1187f ARID1A (c.5270C>T, p.Ala1757Val) Benign 8.68E−05 VUS 0.17 l, m
N/A: not applicable
aIn silico assessment for the suspected variant was performed using three tools, SIFT, PolyPhen, and MutationTaster. A benign or deleterious decision was assigned only if all three tools were in
agreement with regards to the variant. As seen, most of the predictions for the tested variants are conﬂicting and provide little evidence for the functional consequence of the sequence change
bConsensus clustering was only performed if a patient was scored high for CSS/NCBRS
cThe ﬁrst four samples were known cases of the Chr6q25del syndrome, a microdeletion involving the ARID1B gene
dThese subjects were clinically suspected to be a case of CSS (MS0672 and MS1220) or NCBRS (MS1227) but with variants of unknown signiﬁcance (VUS) at the time of assessment
eThe initial clinical evaluations of subjects MS1185 and MS1161 was not available despite their reported variants being classiﬁed as likely pathogenic according to the ACMG guidelines. The classiﬁcations
were made according to the existence of one strong (de novo inheritance), one moderate (absent in population databases), and one supportive (missense variant in a gene with low rates of benign
missense variants—SMARCA2) criterion. The clinical assessment was reviewed after the DNA methylation analysis classiﬁed MS1185, but not MS1161, as a potential case of CSS/NCBRS
fThe remaining samples were assessed due to a VUS report in a BAFopathy-related gene, and the CSS/NCBRS was not the primary clinical assumption. The objective was to screen among carriers of
VUS in a CSS/NCBRS-related gene
gACMG classiﬁcation for this variant was later changed to likely pathogenic following the conﬁrmation of a de novo inheritance
hClinical assessments are in compliance with the suspected syndrome
iThe suspected variant has a de novo inheritance
jAlternative amino acid changes are known in NCBRS at the same codon
kClinical assessments are not in compliance with the suspected syndrome
lNon-truncating variants in ARID1A and ARID1B to cause CSS are rare
mVariant is present in general population at minor allele frequency above zero
nVariant does not induce protein change (synonymous)
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DMR probes <0.05. The analysis was performed on the same sets of cases and
controls used for methylation proﬁling.
Gene-set enrichment analyses. Gene-set enrichment analysis was performed
using the missMethyl package to identify the GO terms overrepresented in the
genes harboring differentially methylated probes45, taking into account the number
of CpG sites per gene. The entire CpG sites tested in the analysis were included as
the background for the enrichment analysis. The enriched GO terms with an FDR
< 0.05 were reported. The redundant GO terms were reduced and visualized as
interactive networks using the REViGO tool46.
Construction of a classiﬁcation model for CSS/NCBRS. To design a classiﬁca-
tion model for CSS/NCBRS, we selected a random 75% subset of the patients with
BAFopathy combined with an age-matched cohort of controls with a sample size
six times larger than the patients. Feature selection was performed in two steps.
First, a multivariate limma regression modeling was conducted to prioritize the
differentially methylated probes which were not confounded by batch structure or
blood cell type composition (incorporated into the model matrix of the regression
analysis as confounding variables). The analysis was restricted to probes showing a
minimum detectable methylation range by microarray technology between the
cases and controls (i.e., 5%). The CpGs were sorted according to the moderated p
values (ascending), and the top 1000 were retained for feature selection. In the
second step, we performed a receiver’s operating curve characteristics analysis for
every probe and identiﬁed those with an AUC > 0.85. Finally, we measured the
pairwise correlations across the probes and removed the highly correlated features
with R2 > 0.85. The remaining probes were used to train a SVM with radial basis
function kernel using e1071 package. To determine the best hyperparameters (cost
and gamma), and to measure the accuracy of the model, a 10-fold cross-validation
was performed. In this process, the training set was randomly divided into 10 folds.
Nine folds were used for training the model and one fold for testing. After
repeating this iteration for all of the 10 folds, the mean accuracy was calculated, and
the hyperparameters with the optimal performance were selected. For every sam-
ple, the model was set to generate a classiﬁcation score between 0 and 1 as the
probability of having a methylation proﬁle related to CSS/NCBRS. This was per-
formed according to the Platt’s scaling method47. The ﬁnal model was applied to
the testing dataset to make sure of the success of the training. The default binary
classiﬁer’s probability score of 0.5 was applied as the classiﬁcation cut-off.
Validation of the classiﬁcation model. We ensured that the model is not sensitive
to the batch structure of the methylation experiment by applying it to all of the
samples assayed on the same batch as the cases used for training. To conﬁrm that
the classiﬁer is not sensitive to the blood cell type compositions, we downloaded
methylation data from isolated cell populations of healthy individuals from GEO
(GSE35069)21 and supplied them to our model for prediction, and examined the
degree to which the scores were varied across different blood cell types. Next, the
model was applied to the testing cohort (25% subset of the patients not used for
feature selection or training) to evaluate the predictive ability of the model on
affected subjects. To determine the speciﬁcity of the model, we supplied three
groups of healthy subjects to the model for scoring: (1) healthy subjects with a
diverse ethnicity background from our internal dataset, (2) publicly available
methylation data from children (GSE104812)22, and (3) publicly available
methylation data from adults (GSE67705)23. To understand whether this model
was sensitive to other medical conditions presenting with developmental delay and
intellectual disabilities, we tested a large number of subjects with a conﬁrmed
clinical and molecular diagnosis of various syndromes (Fig. 8) including patients
with imprinting defect disorders (Angelman syndrome (n= 14), Prader–Willi
syndrome (n= 7), Silver–Russell syndrome (n= 64), and Beckwith–Wiedemann
syndrome (n= 9)), diseases of the epigenomic machinery (Sotos syndrome (n= 9),
Floating–Harbor syndrome (n= 18), Claes–Jensen syndrome (n= 10), Genitopa-
tellar syndrome (n= 3), Cofﬁn–Lowry syndrome (n= 10), ATRX syndrome (n=
19), autosomal dominant cerebellar ataxia with deafness and narcolepsy (n= 5),
Kabuki syndrome (n= 24), CHARGE syndrome (n= 39), Rett syndrome (n=
16)), RASopathies (Noonan syndrome (n= 69), Cardiofaciocutaneous syndrome
(n= 15), LEOPARD syndrome (n= 2)), Fragile X syndrome (n= 50), trisomy 21
(n= 7), and autism spectrum disorders (n= 141).
Screening of undiagnosed and uncertain cases. The ﬁnally conﬁrmed model was
used to score subjects suspected of having a CSS/NCBRS-related phenotype either
with no sequence information available or with variants of unknown signiﬁcance,
as well as those with an uncertain clinical diagnosis. In addition, we used the model
to screen a large group of individuals with various forms of DD/ID but no
established diagnosis in a search for potential cases of CSS/NCBRS. The subjects
who were predicted as CSS/NCBRS were evaluated based on both the clinical and
molecular information. We performed in silico analysis to provide support for the
predictions using SIFT, PolyPhen, and MutationTaster48–50.
Exome sequencing and copy number variant detection. Subjects with no
mutation report, predicted herein as a case of CSS/NCBRS, were sequenced using a
custom designed next-generation sequencing panel covering coding sequences of
~4600 genes developed using SeqCap EZ MedExome probes. These genes are
identiﬁed to be medically relevant by the consortium of the Emory Genetics Lab,
Harvard Laboratory of Molecular Medicine, and Children’s Hospital of Philadel-
phia. Among the CSS/NCBRS-related genes, six are covered by this panel: ARID1A,
ARID1B, ARID2, SMARCB1, SMARCA4, and SMARCA2. To rule out that the
patients do not have other conditions explaining their clinical presentations, we did
not limit the analysis to these six genes and evaluated the entire set of the 4600
genes for a potentially causative variant. Following mapping the raw sequence data
by Burrows-Wheeler aligner, VarDict was used for calling single nucleotide var-
iants and small to moderate size indels51. Detection of large deletions, duplications,
and insertions were performed using Pindel52. In addition, we investigated the copy
number changes in the size of an exon and above using the ExomeDepth algo-
rithm53, which is shown to have an outstanding performance in the detection of
rare CNVs involved in Mendelian disorders54.
Ethics statement. The study protocol has been approved by the Western Uni-
versity Research Ethics Boards (REB ID 106302), and the Hamilton Integrated
Research Ethics Board (REB ID 13-653-T). All of the participants provided
informed consent prior to sample collection. All of the samples and records were
de-identiﬁed before any experimental or analytical procedures. The research was
conducted in accordance with all relevant ethical regulations.
Data availability
DNA methylation microarray data from patients with CSS and NCBRS can be
obtained from Gene Expression Omnibus (GEO) with accession number
GSE116992 . The exome sequencing data analyzed during the current study are not
publicly available as part of the conditions of the research ethical approval of the
study, but are available from the corresponding author on reasonable request.
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